Electrophysiology Devices Market: Advancements in Diagnostic and Therapeutic Tools

The global market for electrophysiology devices was valued at USD 12.9 billion in 2024 and is projected to expand at a Compound Annual Growth Rate (CAGR) of 15.1% from 2025 to 2030.

This growth is driven by several factors:

• Increasing use of EP tests: These tests are crucial for diagnosing and treating heart conditions like atrial fibrillation.

• Rising demand for cardiac rhythm management devices: These devices enable continuous monitoring of heart rhythms.

• Expanding applications in out-of-hospital settings: Electrophysiology devices are increasingly being used outside of traditional hospital settings. 

Gather more insights about the market drivers, restrains and growth of the Electrophysiology Devices Market 

Additionally, the prevalence of heart conditions among younger generations is on the rise due to lifestyle factors such as sedentary behavior, smoking, and excessive alcohol consumption. For instance, the Centers for Disease Control and Prevention (CDC) estimates that approximately 12.1 million Americans will be affected by atrial fibrillation by 2030.

The growing number of catheter ablation procedures is further fueling market growth. As the number of these procedures increases, so does the demand for related products and devices. Moreover, advancements in electrophysiology devices, such as improved maneuverability, flexibility, compatibility, and integrated imaging capabilities, are contributing to market expansion. An article published by Elsevier Inc. in March 2023 highlighted the significant increase in the annual rate of cardiac electrophysiology procedures in the U.S., from 817.9 per 100,000 beneficiaries in 2013 to 1,089.68 per 100,000 beneficiaries in 2019.

Indication Segmentation Insights 

Atrial fibrillation (AFib) emerged as the leading segment in the arrhythmia market in 2024, capturing a significant 73.64% revenue share. This type of arrhythmia is widely recognized as the most common, posing a substantial risk of stroke and blood clots. According to the British Heart Association, a staggering 1.5 million individuals in the UK were grappling with AFib in 2022. Alarmingly, an estimated 270,000 people aged 65 and older in the UK remained undiagnosed, contributing to the segment's substantial share.

The rising prevalence of AFib has spurred the development of innovative solutions, such as smartphone applications. These apps empower patients to connect with healthcare professionals, facilitating remote monitoring and timely intervention. Additionally, healthcare institutions are increasingly incorporating arrhythmia care into their treatment protocols, both in inpatient and outpatient settings. 

Order a free sample PDF of the Electrophysiology Devices Market Intelligence Study, published by Grand View Research.